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ABSTRACT Pulmonary surfactant is a complex mixture of lipids and proteins that forms a surface-active ﬁlm at the air-water
interface of alveoli capable of reducing surface tension to near 0 mN/m. The role of cholesterol, the major neutral lipid com-
ponent of pulmonary surfactant, remains uncertain. We studied the physiological effect of cholesterol by monitoring blood
oxygenation levels of surfactant-deﬁcient rats treated or not treated with bovine lipid extract surfactant (BLES) containing zero
or physiological amounts of cholesterol. Our results indicate no signiﬁcant difference between BLES and BLES containing
cholesterol immediately after treatment; however, during ventilation, BLES-treated animals maintained higher PaO2 values
compared to BLES 1 cholesterol-treated animals. We used a captive bubble tensiometer to show that physiological amounts of
cholesterol do not have a detrimental effect on the surface activity of BLES at 37C. The effect of cholesterol on topography and
lateral organization of BLES Langmuir-Blodgett ﬁlms was also investigated using atomic force microscopy. Our data indicate
that cholesterol induces the formation of domains within liquid-ordered domains (Lo). We used time-of-ﬂight-secondary ion mass
spectrometry and principal component analysis to show that cholesterol is concentrated in the Lo phase, where it induces
structural changes.
INTRODUCTION
Pulmonary surfactant is a complex mixture of lipids and pro-
teins that is secreted by alveolar type II epithelial cells and
adsorbs to the lung air-water interface, where it forms a
surface-active ﬁlm. The ﬁlm reduces the work of breathing
by lowering the surface tension during inspiration. This ﬁlm
can also attain surface tension of near 0 mN/m during ex-
piration and in doing so prevent alveolar collapse at low lung
volumes.
Surfactant is essential for normal lung function. Premature
babies who do not have sufﬁcient amounts of surfactant can
develop respiratory distress syndrome (RDS), a leading
cause of neonatal mortality. Exogenous surfactant is admin-
istered to treat this condition. As well, surfactant treatment
has been investigated with patients with acute lung disease
and acute RDS (1–3).
The chemical composition of pulmonary surfactant is highly
conserved among different animal species. It consists of 80–
90% phospholipids, 3–10% neutral lipids (mainly cholesterol),
and 5–10% surfactant-associated proteins. The major phos-
pholipid present is dipalmitoylphosphatidylcholine (DPPC,
30–45%). Other major components are unsaturated phos-
phatidylcholines (PC, 25–35%), phosphatidylglycerol, and
phosphatidylinositol plus other minor components such as
phosphatidylethanolamine and sphingomyelin (4–7). Surfactant-
associated proteins, SP-B and SP-C, are low molecular
weight, hydrophobic proteins that accelerate surfactant
adsorption and promote the ability to attain low surface
tensions. SP-A and SP-D are hydrophilic glycoproteins.
SP-A affects surfactant lipid structure and plays a role in its
surface activity by binding DPPC and by enhancing effects
due to SP-B (4,8–10).
Cholesterol is the major neutral lipid in pulmonary surfac-
tant with a concentration of up to 10% by mass (20 mol %)
(11,12). The presence of cholesterol in surfactant has long
been known; however, the role of cholesterol in surfactant
remains uncertain. The cholesterol/phospholipid ratio in
pulmonary surfactant has been shown to increase slightly as
a result of exercise (13), to approximately double during lung
injury (14), and to increase by 1.5-fold in heterothermic
mammals undergoing torpor (15). It has recently been re-
ported that physiological levels of cholesterol enhance the
adsorption of surfactant phospholipids to the equilibrium
surface tension of;23 mN/m (16). Other studies have found
that cholesterol enhances adsorption of lipid extract surfac-
tant at 25C but has no signiﬁcant effect at physiological
temperatures (17). These effects of cholesterol on surfactant
adsorption are generally attributed to the ﬂuidizing effects of
the sterol on phospholipid mixtures containing relatively
high levels of DPPC (18,19). However, phospholipid ﬂuid-
ization could impede the ability of such ﬁlms to attain low
surface tensions during compression.
In keeping with this suggestion, early in vitro functional
measurements using a Langmuir-Wilhelmy surface balance
and the pulsating bubble surfactometer (PBS) revealed that
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physiological amounts of cholesterol inhibit the ability of
surfactant to attain low surface tensions (19–26). Accord-
ingly, cholesterol is removed from many clinically used sur-
factant extracts. For example, it is extracted from BLES, the
clinical surfactant used for these studies. However, it is clear
that cholesterol is endogenously present in surfactant, and
surface tensions near zero have been measured in the healthy
lung (27), indicating that cholesterol does not necessarily
interfere with lung function in vivo. The early ﬁndings may
be related to technical difﬁculties. Thus, more recent in vitro
studies using captive bubble tensiometry (CBT) show that
physiological amounts of cholesterol do not affect the sur-
face activity of an artiﬁcial surfactant with chemical com-
position close to natural surfactant (28) or a clinically used
surfactant extract (29).
In this study, we seek to relate the effect of cholesterol in
vivo with that of cholesterol in vitro and to understand how
cholesterol exerts its effects. We studied the physiological
effect of cholesterol by monitoring blood oxygenation levels
of surfactant-deﬁcient rats treated or not treated with a clin-
ically used exogenous surfactant (bovine lipid extract surfac-
tant, BLES) containing zero or physiological amounts of
cholesterol. We use the term ‘‘physiological’’ in reference to
most homeothermic mammals. We also examined the effect
of cholesterol on the surface activity of BLES using CBT.
Various amounts of cholesterol (physiological and higher)
were added to BLES, and changes in surface tension were
observed upon adsorption and during slow compression/
expansion (quasistatic) cycles and fast (dynamic) cycles as in
normal breathing.
The effect of cholesterol on the topography and lateral
organization of BLES Langmuir-Blodgett (LB) ﬁlms was
investigated using atomic force microscopy (AFM). The lo-
cation of cholesterol in BLES LB ﬁlms containing various
amounts of deuterated cholesterol was determined by time-
of-ﬂight-secondary ion mass spectrometry (ToF-SIMS) imag-
ing. Our results show that addition of physiological amounts
of cholesterol (20 mol %) does not inhibit the surface activity
of BLES at 37C, whereas higher amounts (50 mol %) greatly
decrease its ability to attain low surface tension. Based on
our in vivo results, the presence of a physiological amount of
cholesterol has no initial effect on blood oxygenation levels.
Finally, we show that both physiological and supraphysio-
logical levels of cholesterol induce structural changes in
BLES LB ﬁlms.
MATERIALS AND METHODS
Materials
BLES was a generous gift from BLES Pharmaceuticals (London, Ontario,
Canada) and was extracted before use using a modiﬁed Bligh and Dyer
technique explained elsewhere (30). Extracted BLES was stored in chlo-
roform at 20C until use. Cholesterol was obtained from Sigma (St. Louis,
MO), and cholesterol-25,26,26,26-27,27,27-d7 was purchased from CDN
Isotopes (Pointe Claire, Quebec, Canada). Both were received as powders
and were dissolved in chloroform at a concentration of 1 mg/mL and stored
at 20C. All solvents used were high-performance liquid chromatography
grade and were used without further puriﬁcation.
Animal experimentation
Male Sprague-Dawley rats (300–500 g) were used for these experiments
(Charles River, Saint-Constant, Quebec, Canada). All procedures were ap-
proved by the animal use subcommittee of the University ofWesternOntario.
The physiological response of surfactant-deﬁcient animals to administration
of surfactant was determined as previously described (31). Brieﬂy, rats were
anaesthetized, connected to a mechanical ventilator, and made surfactant
deﬁcient by repetitive saline lavage. Subsequently, animals were randomized
into one of three groups: 1), animals receiving 20mg phospholipid/kg BLES,
2), animals receiving 20 mg phospholipids/kg BLES containing 20 mol %
cholesterol, or 3), a nontreated air bolus control group. After treatment the
animals were reconnected to the ventilator for an additional 120 min, during
which time arterial PO2 values were determined at 15 min intervals as an
indication of the physiological properties of the instilledmaterial. All data are
presented as mean6 SE.
Captive bubble tensiometry
The surface activity of the samples was examined by measuring adsorption
and by estimating surface tension of bubbles compressed and expanded in
quasistatic and dynamic modes using a custom designed CBT (32). CBT
experiments were performed in triplicate, using 500-mg/mL samples diluted
in buffer (0.150 mM NaCl, 2 mM Tris-HCl, 1.5 mM CaCl2). After the CBT
chamber was ﬁlled with the desired surfactant in buffer and the temperature
equilibrated at 37C 6 1C, an air bubble 5–8 mm in diameter was intro-
duced. The change in bubble shape was recorded to monitor the adsorption
of the surfactant material to the air-saline interface. After equilibrium surface
tension, geq, was attained, the chamber was sealed, and quasistatic or dy-
namic compression-expansion cycles of the bubble were performed.
Changes in bubble area were recorded during each individual experiment
and the bubble shapes analyzed using custom designed software to calculate
the surface tension of the ﬁlm (32,33).
For quasistatic experiments, the pressure in the sample chamber was
increased stepwise by turning the plunger 5–10 (;10% of bubble volume
per step) and waiting 10 s for equilibration after each step. Four quasistatic
cycles were performed with an intercycle delay of 4 min on return to original
volume. The minimum surface tension, gmin, was achieved when the bubble
decreased in size without any further ﬂattening on increasing the chamber
pressure. Dynamic modes were performed in separate experiments by cy-
cling the bubble at 25 cycles/min. The surface area of the bubble was
reduced until the ﬁlm reached gmin (a value known from quasistatic ex-
periments) and then expanded to 100–120% of original area and cycled
between these two limits. All data are presented as mean 6 SE.
Langmuir-Blodgett transfer
Surfactant ﬁlms were prepared by spreading chloroform solutions of BLES
containing various amounts of deuterated and nondeuterated cholesterol
onto 90 mL of doubly distilled water (pH of 7.06 0.5) in a Langmuir trough
(m-trough-SE by Kibron, Helsinki, Finland) at ambient temperature (24C6
1C). The ﬁlms were allowed to equilibrate for 10 min before compression
at 0.02 nm2 molecule1 min1 until the desired pressure of 30 mN/m was
reached. Monolayer ﬁlms were deposited onto substrates by elevating the
previously submerged substrates vertically through the air-water interface at
a rate of 2.0 mm/min. Freshly cleaved mica was used as a substrate for AFM
studies, and gold-coated mica was used for ToF-SIMS studies. Gold-coated
mica was prepared by inserting freshly cleaved 1 3 1 cm2 pieces of mica
into a Hummer VI sputtering system (Technics EM, Springﬁeld, VA) under
reduced pressure at 100 mTorr. The Au was sputtered onto the substrate for
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10 min at a plate current of 10 mA. Deposited ﬁlms were imaged within 2 h
of deposition.
Cholesterol depletion
Two procedures were used to extract cholesterol from the surfactant ﬁlm,
both utilizingmethyl b-cyclodextrin. In the ﬁrst procedure, BLES1 20 mol%
cholesterol was spread onto 90 mL of 1 mM methyl b-cyclodextrin and
incubated for 1 h. The ﬁlm was then compressed to a surface pressure of
30 mN/m and deposited on mica as described above and imaged by AFM. In
the second procedure, BLES 1 20 mol % cholesterol was spread onto
doubly distilled water and compressed to the desired pressure of 30 mN/m.
Concentrated methyl b-cyclodextrin was then introduced in the subphase
to give a ﬁnal concentration of 1 mM. After 1 h incubation, the ﬁlm was
deposited onto mica and imaged by AFM. Results obtained from the two
procedures were identical.
Atomic force microscopy
Topographical atomic force microscope images were obtained using a
Nanoscope III scanning force multimode microscope (Digital Instruments,
Santa Barbara, CA). Samples were scanned in contact mode in air within 2 h
of deposition. A silicon nitride cantilever was used with a spring constant of
0.3 N/m, and the scanner was of the J type. Image analysis was performed
using the Nanoscope III software (version 5.12r3).
ToF-SIMS imaging
ToF-SIMS images were collected using an ION-TOF ToF-SIMS IV (ION-
TOF, Muster, Germany) with a pulsed 25 keV 69Ga1 primary ion beam in
‘‘burst-alignment’’ current mode. This mode uses a pulse width of 200 ns, a
spot size in the 250 nm range, and unit mass resolution. All images obtained
were 2563 256 pixels. From previous studies (34), it is known that the static
limit for these materials is passed at ;8 3 1012 ions/cm2. Generally, an ion
dose of,53 1012 ions/cm2 was used for these analyses (equivalent to;10
scans for a 1003 100 mm2 image at 1 pA primary ion current and 3 scans for
a 50 3 50 mm2 image at 1 pA).
Principal component analysis evaluation
Multi-ion SIMS 1.2 was the software used for principal component analysis
(PCA) examination of negative and positive ToF-SIMS images of BLES 1
30 mol % cholesterol-d7 samples. As many signiﬁcant peaks as possible
were added to the peak list for analysis. The total remaining ion image (sum
of ion intensity not selected as a speciﬁc peak) was also added to the peak list
since it contains a signiﬁcant amount of topographic and matrix information.
Details of data processing are available elsewhere (34). PCA results are
summarized in two ways: a table containing the fragments used in the peak
list with corresponding loading value and an image with dimensions of
the original image showing the score value of each pixel as a function of
position.
RESULTS
The effect of cholesterol on arterial blood oxygenation levels
was examined in surfactant-deﬁcient rats. Fig. 1 shows the
arterial blood oxygenation values of animals randomized to
our three experimental groups. Surfactant-deﬁcient animals
that did not receive a surfactant treatment had PaO2 values
that remained low over the entire experimental procedure.
Both groups of animals that received exogenous surfactant
(BLES and BLES 1 20 mol % (10% wt/wt) cholesterol),
exhibited PaO2 values that increased signiﬁcantly immedi-
ately after treatment and reached levels signiﬁcantly higher
than the nontreatment group. Comparison of the two treat-
ment groups revealed no signiﬁcant difference in PaO2 value
immediately after treatment; however during ventilation
animals receiving BLES reached higher PaO2 values than
those in the BLES-cholesterol group. The differences were
statistically signiﬁcant at 60 min after ventilation. These
results, which indicate a physiological difference between
BLES and BLES 1 cholesterol, prompted us to further in-
vestigate the biophysical and structural properties that may
be associated with the presence of cholesterol in surfactant.
The biophysical properties, including adsorption and sur-
face tension reduction during both quasistatic and dynamic
compression-expansion cycles, were analyzed on a CBT
(Figs. 2–4). Adsorption isotherms illustrate how rapidly a
substance spreads at the air-water interface to form a ﬁlm that
lowers the surface tension to the equilibrium value. Adsorp-
tion isotherms for BLES containing 0, 20, and 50 mol %
cholesterol are shown in Fig. 2. BLES containing 0 or 20
mol % cholesterol spread faster than BLES containing 50
mol % cholesterol; however, within 30 min, all ﬁlms attained
equilibrium surface tension, geq.
In addition to spreading quickly, a functional surfactant
should reach a surface tension close to zero upon subsequent
compression. Films at equilibrium were subjected to four
quasistatic compression-expansion cycles. Isotherms were
prepared and are shown for cycles 1 and 4 in Fig. 3. BLES
with and without 20 mol % cholesterol reached low surface
tensions (2–5 mN/m) during the initial quasistatic compres-
sion. Film compressibility (here deﬁned as the % surface area
FIGURE 1 Mean arterial blood oxygenation (PaO2) after air bolus (:,
n ¼ 5), 20 mg phospholipids (PL)/kg body weight BLES (¤, n ¼ 5) and
20 mgPL/kg BLES 1 20 mol % cholesterol (n, n ¼ 5). Animals were
ventilated with 100% oxygen. a ¼ p , 0.05 BLES or BLES 1 cholesterol
versus air bolus, b ¼ p , 0.05 BLES versus BLES 1 cholesterol by two-
way ANOVA.
Effect of Cholesterol on BLES 1393
Biophysical Journal 93(4) 1391–1401
reduction required to reduce g from equilibrium to 0 mN/m)
was slightly lower with 20 mol % cholesterol. The BLES 1
50 mol % cholesterol sample proved incapable of lowering g
below 10 mN/m and ﬁlm compressibility was high. With
all three samples, g increased dramatically during surface
area expansion. BLES and BLES 1 20 mol % cholesterol
exhibited good respreading once equilibrium g was attain-
ed resulting in gmax levels around 25 mN/m.
The BLES 1 50 mol % cholesterol sample showed ham-
pered respreading such that gmax was close to 30 mN/m.
Nevertheless, by quasistatic cycle 4, although BLES was
able to attain g-values below 5 mN/m, gmin remained slightly
higher than with the 20 mol % sample. In addition, BLES
compressibility was slightly greater than with the 20 mol %
cholesterol-containing BLES, which required a surface area
reduction of ;12% comparable with that of spread DPPC
ﬁlm (4,33). In contrast, the ability of the 50 mol % cholesterol
sample to attain low g did not improve but rather deterio-
rated, likely as a result of poor PL respreading to equilibrium
and instability at low surface tension. The cholesterol-free
BLES sample exhibited a small but distinct hysteresis. The
BLES containing 20 mol % cholesterol sample demonstrated
lowered expandability such that g during ﬁlm expansion re-
mained close to the compression values, virtually obliterating
hysteresis. This indicates that the resulting ﬁlm compression-
expansion characteristics have become almost perfectly revers-
ible. The high cholesterol sample continued to demonstrate
signiﬁcant hysteresis.
Dynamic compression-expansion cycling permits evalua-
tion of surfactant ﬁlms under conditions resembling normal
breathing (25 cycles/min). All three samples showed some
improvement by the 21st cycle. The BLES and BLES 1 20
mol % cholesterol samples both attained gmin near 0 and
gmax values below 30mN/m. Although the BLES1 50mol %
cholesterol sample demonstrated the greatest relative im-
provement, gmin remained high and gmax was .30 mN/m.
The effect of cholesterol on BLES was investigated by
determining the effect of this sterol on the structural orga-
nization of monolayers of BLES and BLES containing 20
mol % cholesterol deposited on mica. The ﬁlms were imaged
by AFM in contact mode. The pressure-area isotherm for a
monolayer of BLES has been previously reported (35). The
isotherm shows a continuous, broad coexistence region of
FIGURE 2 Adsorption isotherms of BLES containing increasing amounts
of cholesterol. Isotherms were constructed by monitoring adsorption of 500
mg/ml BLES in the absence or presence of cholesterol in the CBT at 37C.
FIGURE 3 Quasistatic compression
(d)-expansion (s) isotherms of BLES
containing increasing amounts of cho-
lesterol. Isotherms were constructed by
averaging three independent experiments
for the ﬁrst and fourth compression-
expansion cycles. An intercycle delay
of 4 min was used to allow the system
to reequilibrate.
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liquid condensed (LC) and liquid expanded (LE) phases
from low pressures to;42–45 mN/m. All ﬁlms studied here
were deposited onto mica at 30 mN/m, which falls in the
normal coexistence region. Fig. 5 A, a typical AFM height
image obtained for BLES monolayers, shows the presence
of circular LC domains in a LE environment. These LC
domains form in two sizes: those with an average diameter
of ;10 mm microdomains and those with diameters in the
range of 100–150 nm nanodomains. Fig. 5 B shows that
these domains are relatively homogeneous topographically.
Height analysis of BLES monolayers (Fig. 5 C) shows that
the average height of LC micro- and nanodomains are both
0.9 6 0.01 nm above the surrounding LE phase. The dif-
ference in height between LC and LE regions arises from the
different composition and molecular tilt of lipids in the two
phases.
Fig. 5 D is a typical AFM height image for a sample of
BLES with 20 mol % cholesterol. In the presence of
cholesterol, the number of microdomains increases and the
average size decreases (radius ranging 3–6 mm). Nano-
domains are still present at similar overall densities and sizes.
The presence of cholesterol in BLES also induces the
formation of domains within microdomains, as evident in
Fig. 5 E. Height analysis of these AFM images (Fig. 5 F)
shows that the height difference between nanodomains and
Ld phase is still 0.9 6 0.01 nm; however, the height
difference between new domains within microdomains and
the liquid-disordered (Ld) phase is 1.1 6 0.01 nm (i.e., the
new domains rise 0.2 nm above the microdomain). BLES
containing cholesterol corresponding to ;10 mol % also
yielded AFM images of domains within domains (results not
shown).
The role of cholesterol in domain formation was further
investigated by removing cholesterol from the surface ﬁlm.
Monolayers of BLES 1 20 mol % cholesterol were com-
pressed to a surface pressure of 30 mN/m to allow the for-
mation of domains within domains. A solution of methyl
b-cyclodextrin was injected into the subphase since it is
known to bind and remove cholesterol from membranes. The
monolayer was deposited on mica and imaged by AFM.
Fig. 5 G shows that both micro- and nanodomains are pres-
ent, but there are no domains within the microdomains (Fig.
5,H and I ). However, the size of the microdomains increased
to 5–10 mm and the number of nanodomains was decreased.
Nevertheless, in general, removal of cholesterol by methyl
b-cyclodextrin leads to the same phase behavior as BLES
without added cholesterol (Fig. 5, A–C).
AFM images reveal the structural organization of LB ﬁlms
but not the chemical composition of the different phases. The
key question is where is the cholesterol? ToF-SIMS can
image the distribution of masses across the sample, thereby
providing information about the distribution of chemical
species on the surface. However, it is difﬁcult to detect mass
fragments uniquely due to cholesterol; so we have resorted to
using a speciﬁcally deuterium-labeled analog of cholesterol:
cholesterol-d7, which contains seven deuterons in the iso-
propyl group. BLES samples containing 0 and 30 mol %
cholesterol-d7 were deposited on gold-coated mica and
imaged by ToF-SIMS. The amount of cholesterol was
increased from 20 mol % used in AFM studies to 30 mol %
FIGURE 4 Dynamic compression (d)-
expansion (s) isotherms of BLES con-
taining increasing amounts of cholesterol.
Isotherms were constructed by averaging
three independent experiments for the ﬁrst
and 21st compression-expansion cycles.
Adsorbed ﬁlms were cycled at 25 cycles/
min.
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in ToF-SIMS studies as an attempt to increase the signal
and therefore obtain better images showing the location of
cholesterol.
LB ﬁlms of BLES containing 30 mol % cholesterol-d7
were imaged by AFM and showed similar topographical
features as LB ﬁlms of BLES 1 20 mol % cholesterol (re-
sults not shown). Imaging in the negative mode (anionic
mass fragments), palmitate is detected as the fragment with
mass/charge ratio (m/z) 255. The microdomains are seen to
contain a large proportion of palmitate (Fig. 6, A and B), as
would be expected if they contain principally DPPC. The
diameter of these palmitate-rich domains is similar to that
obtained from AFM images of the microdomains. The pal-
mitate signal appears stronger for the BLES sample com-
pared to the BLES1 30 mol % cholesterol-d7 (Fig. 6, A and
B) due to changes in the physical environment of the lipids
that contain palmitate. The ToF-SIMS does not have the
resolution to detect the nanodomains as individual units.
Reference mass spectra were obtained for pure cholesterol-
d7 and BLES in both the positive and negative detection
mode to determine speciﬁc mass peaks that could be used to
identify cholesterol. In the negative ion mode, the only
speciﬁc fragment with high enough intensity to provide an
image with information about the location of cholesterol was
at mass/charge ratio (m/z) 2 due to deuterium. Fig. 6 C shows
the absence of signal when imaging at mass 2 in the negative
ion mode of a BLES sample, due to the absence of deuterated
cholesterol. In contrast, Fig. 6 D shows an intense mass 2
signal from the microdomains, indicating that deuterium, and
therefore cholesterol, is highly concentrated in these do-
mains. Based on our ToF-SIMS images, we cannot exclude
the possibility that cholesterol is present in the Ld phase as
well. Fig. 6, E–H, was obtained by subjecting Fig. 6, A–D, to
a smoothing function that enhances the contrast to more
clearly show the location of palmitate and deuterium.
Comparison of Fig. 6, F and H, shows that deuterium is
highly concentrated in microdomains of all diameters. At this
time we cannot determine whether the cholesterol is present
in the domains within the microdomains to a greater or lesser
extent.
PCA of 50 3 50 mm2 negative ion mode images of
BLES 1 30 mol % cholesterol-d7 resulted in the identiﬁ-
cation of two principal components (PC1 and PC2) where
PC2 gives a very clear image of the two phases. An example
of an image score is presented in Fig. 7 A, with correspond-
ing factor loadings presented in Fig. 7 B. Positive loadings
represented graphically in Fig. 7 B correspond to mass
fragments that are found in the Ld phase. The more positive
the loading the stronger the correlation is. Conversely, nega-
tive loadings will correspond to mass fragments found in the
microdomains. In negative ion mode, strong speciﬁc frag-
ments for cholesterol-d7 are found at the following m/z: 2,
77, 232, 233, 391, and 393. The respective loadings for these
fragments are negative, indicative of the microdomains.
Thus the PCA results also indicate that cholesterol is highly
concentrated in the microdomains.
FIGURE 5 AFM height images of
BLES (A and B) and BLES1 20 mol %
cholesterol (D and E). Samples were
spread on a liquid-air interface and com-
pressed to a surface pressure of 30 mN/m
at 24C.G andH are AFM height images
of BLES 1 20 mol % cholesterol ex-
posed to 1 mM methyl b-cyclodextrin
for 1 h at 24C. Film transfer was per-
formed using the LB method onto mica.
The ﬁlm was scanned in air in contact
mode. Images A, D, and G are 60 3 60
mm2, B and E are 4 3 4 mm2, and H is
8 3 8 mm2, and were collected from
the boxed areas shown. C, F, and I are
height analysis proﬁles for B, E, and H,
respectively, along the lines shown.
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AFM height images of monolayers of BLES containing 50
mol % cholesterol deposited at 30 mN/m show the presence
of two phases (Fig. 8 A). Higher magniﬁcation AFM height
images were collected (Fig. 8 B) which were subjected to
height analysis (Fig. 8 C) to give a height difference between
the two phases of 0.65 6 0.03 nm. In the presence of high
amounts of cholesterol, microdomains (,10 mm in diame-
ter) are still observed as well as large Lo domains that contain
holes. ToF-SIMS images were used to determine the location
of cholesterol in these samples as well. In the negative ion
mode, images of m/z 255 (Fig. 8 D) (representing palmitate)
show the presence of two phases. Images of m/z 2 (Fig. 8 E)
(corresponding to deuterium) show that the cholesterol colo-
calizes with the palmitate—presumably in the more ordered
phase. Images shown in Fig. 8, D and E, were smoothed to
enhance the contrast for a better picture of the location of
palmitate and deuterium with the results shown in Fig. 8, F
and G.
DISCUSSION
The presence of cholesterol in lung surfactant has long been
known. However, its function has remained uncertain. We
have attempted to clarify surfactant-cholesterol interactions
using in vivo and in vitro biophysical and surface topography
approaches. The addition of cholesterol to LC phase phos-
pholipids, such as pure DPPC, results in the formation of a
more ﬂuid Lo phase (16,36). Increased ﬂuidity could lead to
enhanced adsorption as has been observed with lipid mix-
tures containing DPPC (18,19,25) and with organic solvent
lipid extracts of natural surfactant (16,37). However, al-
though physiological levels of cholesterol-enhanced adsorp-
tion of BLES at 24C, no effect was observed at 37C (17).
In addition, this study showed that the addition of physio-
logical amounts of cholesterol (20 mol %) did not affect
BLES adsorption, indicating that BLES ﬂuidity at 37C was
sufﬁcient to support maximal adsorption to the equilibrium
surface tension of;23 mN/m. The basis of the differences in
the results obtained by different groups is not understood, but
these ﬁndings are consistent with the observation that BLES
and BLES 1 20 mol % cholesterol have similar immediate
effects on oxygenation of surfactant-depleted rats (Fig. 1).
The addition of cholesterol to ﬂuid LE PC membranes
leads to the formation of Ld phase, which possesses ﬂuidity
intermediate between LE and Lo. It is known that cholesterol
possesses higher afﬁnity for DPPC than unsaturated PCs
(38). However, addition of supraphysiological levels of
cholesterol (50 mol %) exceeds the DPPC content of BLES,
apparently resulting in the formation of the Ld as well as the
Lo phase. Increasing the amount of cholesterol to exceed the
maximum DPPC/cholesterol stoichiometry forces the cho-
lesterol to interact with unsaturated phospholipids. This
would agree with the work by Bernardino et al. who show
that removal of cholesterol from porcine surfactant bilayers
leads to a phase transition from ﬂuid ordered/ﬂuid disordered
to gel/ﬂuid (16). The decreased adsorption of BLES con-
taining 50 mol % cholesterol (Fig. 2) is consistent with the
poor in vivo and in vitro properties of cholesterol-rich sur-
factant recovered from rats with acute lung injury (14).
Although the increased ﬂuidity arising from cholesterol
addition could, at least theoretically, lead to enhancement of
surfactant adsorption, it should result in hampered ﬁlm
stability. In keeping with this prediction, the presence of
cholesterol greatly diminished the ability of organic solvent
lipid extract surfactants to attain low surface tensions near 0
mN/m when assayed with the Langmuir-Wilhelmy surface
balance or PBS. For this reason, cholesterol is removed from
some natural surfactant-based clinical lipid extract surfac-
tants such as BLES, Curosurf, and Survanta. However, more
recent studies using the technically superior CBT have re-
ported that physiological amounts of cholesterol do not alter
FIGURE 6 ToF-SIMS negative ion images of two BLES LB ﬁlms con-
taining 0 mol % (A and C) and 30 mol % (B and D) cholesterol-d7. M255
corresponds to the palmitate group, M2 to deuterium present in the tail of
cholesterol-d7. Images E–H were obtained by subjecting A–D, respectively,
to a smoothing function available as part of the ION-TOF software and show
more clearly the location of the palmitate group and deuterium. Images are
50 3 50 mm2, 256 3 256 pixels with 1 shot/pixel.
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the biophysical function of surfactant when using materials
derived from native surfactant or artiﬁcial surfactants of
close to natural composition (16,29).
In agreement, our studies found that 20 mol % cholesterol
did not affect the initial adsorption kinetics (Fig. 2) and led to
slightly lower surface tensions during compression with
quasistatic and dynamic in vitro CBT experiments (Figs. 3
and 4). In contrast, high concentrations of cholesterol (50
mol %) clearly had detrimental effects on spreading kinetics
as well as the ability to attain low g-values (Figs. 3 and 4).
The observations are consistent with recent studies by
Gunasekara et al. (29), who observed that whereas 20 mol %
cholesterol did not affect BLES adsorption or the ability to
attain low tensions, elevating cholesterol to 40 mol %
abolished normal surfactant function. Interestingly, they also
found that addition of DPPC to BLES containing high
cholesterol so that the stoichiometry of the DPPC/cholesterol
complex was restored, recovered the ability of the ﬁlm to
reach low surface tension. Since the level of cholesterol is
higher in acutely injured lungs, it is possible that elevated
levels of cholesterol could contribute to surfactant failure in
acutely injured lungs (14). In these latter studies, cholesterol
was present in the functional large aggregate surfactant
fraction, indicating that cholesterol was an inherent part of
pulmonary surfactant. The cholesterol content of large ag-
gregate fraction increased with lung injury, suggesting the
increase in cholesterol was not attributable to the inﬂux of
lipoproteins. Nevertheless, this possibility remains an im-
portant area for further research.
In the past, surfactant function has been explained by
the generation of a surfactant monolayer which becomes
highly enriched in the gel phase lipid DPPC during repeated
compression-expansion cycling. More recent studies provide
evidence indicating that surfactant may function as a multi-
layer, rather than a monolayer (5,29,33,39–41). Moreover, un-
der certain conditions the pure ﬂuid phospholipid, 1-palmitoyl,
2-oleoyl phosphatidylcholine (POPC), can attain surface ten-
sions near zero at 37C (36,42–45). Thus solid LC phase
lipids such as DPPC are not absolutely necessary for a mono-
layer to attain near zero surface tension at physiological
temperatures in vitro. On the basis of these results we pro-
pose that the ability of surfactant to withstand sufﬁcient sur-
face pressure to attain near zero surface tension depends on
dynamic surfactant ﬁlm organization rather than on dynamic
alterations in surface ﬁlm composition, such as DPPC
FIGURE 8 (A and B) AFM height images of BLES 1 50 mol % chole-
sterol. Samples were spread on a liquid-air interface and compressed to a
surface pressure of 30 mN/m at 24C. Film transfer was performed using the
LBmethod onto mica. The ﬁlm was scanned in air in contact mode. Image A is
60 3 60 mm2 and B is 4 3 4 mm2 and was collected from the boxed area
shown in A. C is a height analysis proﬁle for B along the line shown. (D and E)
ToF-SIMS negative ion images of BLES 1 50 mol % cholesterol-d7. M255
corresponds to the palmitate group, M2 to deuterium present in the tail of
cholesterol-d7. Images F and G were obtained by subjecting A and B, re-
spectively, to a smoothing function available as part of the ION-TOF software
and show more clearly the location of the palmitate group and deuterium.
Images D–G are 50 3 50 mm2, 256 3 256 pixels with 1 shot/pixel.
FIGURE 7 (A) Image scores for PC2 obtained from
PCA of ToF-SIMS negative ion mode images of a BLES1
30 mol % cholesterol-d7 LB ﬁlm. Image is 50 3 50 mm2.
(B) Corresponding loadings for PC2 where negative
loadings correspond to the liquid-ordered domains shown
in blue, and positive loadings correspond to the liquid-
disordered phase shown in yellow.
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enrichment. We have employed AFM and ToF-SIMS to
examine organization in the presence and absence of cho-
lesterol.
Two interesting observations were made during AFM stud-
ies of surfactant ﬁlms in the presence of physiological amounts
of cholesterol. First, there was an increase in the number of
microdomains and a decrease in their size (Fig. 5D). Second,
there was the formation of new domains within the micro-
domains (Fig. 5 E) with a height difference of;0.2 nm. The
effects observed are due to cholesterol since its removal with
methyl b-cyclodextrin removes the domains within the micro-
domains and also leads to the formation of fewer, larger
microdomains (Fig. 5, G and H). The change in domain size
after addition of cholesterol could be a kinetic or thermo-
dynamic effect. The addition of cholesterol could lead to an
increase in the number of nucleation sites, which could lead
to the formation of more domains. Addition of cholesterol
could also lead to a decrease in line tension, which could also
explain the formation of more, smaller domains. We con-
sider the latter explanation to be more likely.
The observed height difference in our AFM data would
most likely be due to the interaction between cholesterol and
DPPC, which leads to an increased ordering of the hydro-
carbon chains of this phospholipid. The formation of domains
within the microdomains is not a result of protein aggrega-
tion since the same effect was observed when 20 mol % cho-
lesterol was added to a mixture of 50:30:20 DPPC/POPC/
POPG (E. Keating, R. Veldhuizen, F. Possmayer, and N. O.
Petersen, unpublished data). Based on our ToF-SIMS results,
it appears that the cholesterol is concentrated in the micro-
domains. At this stage, however, it is impossible to determine
whether cholesterol is preferentially in the domains within the
microdomains. It is possible that some cholesterol is located
in the nanodomains even though we did not observe an increase
in the height of these domains in the presence of cholesterol.
This could be due to the small amount of cholesterol present
here, which may not induce a detectable height difference.
Our ﬁnding of cholesterol in Lo domains agrees with the
composition of lipid rafts found in mammalian plasma
membranes. Rafts are liquid domains enriched in cholesterol,
saturated long-chain phospholipids, and certain proteins and
play important roles in various cellular functions such as
signaling and endocytosis (46–48). Our results also agree
with a previous AFM study where LB ﬁlms of DPPC 1
cholesterol were shown to be thicker than DPPC ﬁlms alone
(49). It is accepted that saturated phospholipids like DPPC
are present in the LC domains, whereas the main constituents
of the more ﬂuid LE phase are unsaturated phospholipids
like POPC and POPG. Additions of cholesterol to phospho-
lipids result in the formation of intermediate Lo phases
within DPPC and with high cholesterol Ld phases in the case
of unsaturated ﬂuid phospholipids. Interestingly, as we in-
creased the concentration of cholesterol to 50 mol %, the
percolation threshold was crossed and the large Lo domains
became connected with Ld islands trapped within (Fig. 8 A).
Despite being continuous, these large Lo domains are not suf-
ﬁciently stable to allow compression to low surface tension
on the CBT (Fig. 4).
Our AFM data provide information about changes in the
structural organization of surfactant at the surface upon cho-
lesterol addition; however, they provide no information about
the location of cholesterol in the ﬁlms. Recently, ToF-SIMS
imaging techniques have been used to obtain chemical maps
of deposited monolayer ﬁlms with submicron resolution.
Here, we added deuterated-cholesterol to BLES and used the
m/z 2 in negative ion mode to identify the location of cho-
lesterol. Since there is no other source of mass units of two in
negative ion mode, we conclude that cholesterol is highly
enriched in the microdomains (Fig. 6,D andH). The signal is
too weak to establish whether cholesterol is present specif-
ically in the domains within microdomains. Our PCA results
conﬁrm that cholesterol is enriched in themicrodomains where
it remains even at elevated levels of 50 mol % cholesterol
(Fig. 8, E and G).
CONCLUSION
Our studies show that, although physiological levels of cho-
lesterol do not interfere and may slightly improve the in vitro
biophysical properties of BLES, this preparation lacks the
ability to maintain good gas exchange in surfactant-deﬁcient
rats. We speculate that the change in PaO2 over time is due to
the way BLES1 cholesterol is handled in the airspace rather
than its biophysical properties. This area needs further in-
vestigation. It has been shown that the level of cholesterol
increases after acute lung injury. We show that surfactant con-
taining supraphysiological amounts of cholesterol loses its
ability to reach low surface tension. Our AFM results pro-
vide information about the lateral organization of BLES
ﬁlms containing no, physiological, and supraphysiological
amounts of cholesterol. These results indicate that addition
of cholesterol leads to the formation of a highly ordered Lo
phase which slightly improves the activity of BLES. How-
ever, addition of cholesterol to exceed the amount of satu-
rated PL leads to the formation of Ld which has a detrimental
effect on the activity of surfactant.
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